New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:04 EDTISISIsis Pharmaceuticals announces results of antisense targeting of HBV
Isis Pharmaceuticals announced that treatment with an antisense compound targeting hepatitis B virus produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These preclinical data demonstrate that antisense targeting of HBV RNA could be an effective approach to treating patients with chronic HBV infection. In this study, an antisense compound targeting HBV produced dose-dependent reductions of HBV-associated antigens, including HBsAg, which is present in both acute and chronic infections and is associated with a poor prognosis in patients with chronic HBV infection. In addition, other measures of viral infection were reduced in both the liver and serum in this mouse model of disease.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:32 EDTISISJPMorgan Smid biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 22, 2015
16:25 EDTISISIsis Pharmaceuticals reports positive data from ISIS-TTR Rx
Subscribe for More Information
April 20, 2015
07:20 EDTISISAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use